📰 Hartmutj Ehrlich News
Page 4 - Hartmutj Ehrlich News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hartmutj Ehrlich. Real-time updates on events, politics, business and more.
January 5, 2023
EQS-News: ABIVAX / Key word(s): Scientific publicationAbivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action 05.01.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax publishes novel data with respect to obefazimod’s anti-inflammat...
January 5, 2023
The scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology describes obefazimod's capacity to selectively up-regulate a single microRNA, miR-124, leading to decreases
December 20, 2022
EQS-News: ABIVAX / Key word(s): StudyAbivax receives FDA agreement on pediatric development plan with obefazimod in IBD 20.12.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax receives FDA agreement on pediatric development plan with obefazimod in IBDThe FDA agreed on...
December 20, 2022
EQS-News: ABIVAX / Key word(s): Study Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD 20.12...
December 14, 2022
EQS-News: ABIVAX / Key word(s): Conference Abivax to attend the J.P. Morgan 41st Annual Healthcare Conference 14.12.2022 / 18:...
December 14, 2022
EQS-News: ABIVAX / Key word(s): ConferenceAbivax to attend the J.P. Morgan 41st Annual Healthcare Conference 14.12.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX TO ATTEND THE J.P. MORGAN 41ST ANNUAL HEALTHCARE CONFERENCEAbivax’s senior executive management wil...
December 14, 2022
Abivax's senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event from January 9-12 in San Francisco, USPARIS
October 15, 2022
Abivax announced that the first U.S. patient has been enrolled in its global phase 3 clinical trial of its oral small-molecule inhibitor obefazimod for the treatment of moderate to severe ulcerative colitis. The trial will include two induction studies – ABTECT-1 (ABX464-105) and ABTECT-2 (ABX464-106) – and a subsequent ABTECT maintenance trial (ABX464-107) that will investigate 25
October 11, 2022
First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the US1,200 UC patients across 36 countries
September 6, 2022
DGAP-News: ABIVAX / Key word(s): Study Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the La...